Inactive Instrument

Akers Biosciences Inc Stock Nasdaq

Equities

US00973E1029

Sales 2022 - Sales 2023 - Capitalization 13.17M
Net income 2022 -15M Net income 2023 -4M EV / Sales 2022 -
Net cash position 2022 4.69M Net cash position 2023 4.87M EV / Sales 2023 -
P/E ratio 2022
-2.94 x
P/E ratio 2023
-1.46 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 58 17-08-07
Director of Finance/CFO 51 21-01-28
- -
Members of the board TitleAgeSince
Chief Executive Officer 58 17-08-07
Chairman 54 18-09-05
Director/Board Member 63 17-08-07
More insiders
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company's product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin and for on- and off-the-job alcohol safety initiatives. The Company's primary focus is on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.
Sector
-
More about the company